Ascendis Pharma A/S(ASND)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,898 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ASND
Events flagged as statistical outliers against ASND's own multi-year baseline — not fixed dollar thresholds.
- Record insider buy2026-08-14
Largest insider buy on record for ASND: BIENAIME JEAN JACQUES purchased $270,435
View source filing →
ASND Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Ascendis Pharma A/S (ASND), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASND at 44.8/100 on a 32-signal composite quality model, placing it at rank #1,898 of 2,961 stocks — the bottom half of the AI-ranked universe. ASND scores in the top quartile across revenue growth (95.1). Areas of concern include institutional flow (2.0) and balance sheet strength (11.0), which score below median versus the broader universe. Top institutional holders of ASND by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Avoro Capital Advisors, based on the most recent SEC filings. ASND trades on the Nasdaq exchange and files with the SEC under CIK 1612042. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASND daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ascendis Pharma A/S directly from SEC EDGAR. Ascendis Pharma A/S's 13F Pro composite quality score has ranged between 43 and 47 since 2026, currently 44.8 — a stable long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+98.0% YoYTotal Assets
+10.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $720.1M +98.0% | $363.6M +36.3% | $266.7M +421.2% | $51.2M +557.9% | $7.8M +11.9% | $7.0M |
| Total Assets | $1.30B +10.4% | $1.18B +42.9% | $825.6M -24.2% | $1.09B +0.4% | $1.08B +10.7% | $979.8M |
Get alerted when ASND's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Ascendis Pharma A/S including:
Top Institutional Holders of ASND
RA CAPITAL MANAGEMENT, L.P.
$2.7B10,281,496 shT. Rowe Price Investment Management, Inc.
$1.8B6,754,846 shAvoro Capital Advisors LLC
$1.4B5,111,111 shWESTFIELD CAPITAL MANAGEMENT CO LP
$1.3B4,798,267 shJupiter Topco LLC
$973.4M3,648,772 shFMR LLC
$945.7M3,545,575 shArtisan Partners Limited Partnership
$702.5M2,634,024 shBlackRock, Inc.
$589.9M2,211,833 shCapital International Investors
$530.4M1,988,614 shMASSACHUSETTS FINANCIAL SERVICES CO /MA/
$500.1M1,875,301 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $2.7B | 10,281,496 |
| T. Rowe Price Investment Management, Inc. | $1.8B | 6,754,846 |
| Avoro Capital Advisors LLC | $1.4B | 5,111,111 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $1.3B | 4,798,267 |
| Jupiter Topco LLC | $973.4M | 3,648,772 |
| FMR LLC | $945.7M | 3,545,575 |
| Artisan Partners Limited Partnership | $702.5M | 2,634,024 |
| BlackRock, Inc. | $589.9M | 2,211,833 |
| Capital International Investors | $530.4M | 1,988,614 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $500.1M | 1,875,301 |
Companies Similar to ASND
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Tarsus Pharmaceuticals, Inc.
RHYTHM PHARMACEUTICALS, INC.
Valneva SE
MADRIGAL PHARMACEUTICALS, INC.
PTC THERAPEUTICS, INC.
Legend Biotech Corp
BridgeBio Pharma, Inc.
Mirum Pharmaceuticals, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ASND on your watchlist
Track score changes the day Ascendis Pharma A/S files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ASND a good stock to buy?
13F Pro's AI-powered analysis of Ascendis Pharma A/S (ASND) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASND are available on the ASND stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ASND is classified as a large company.
Which hedge funds own ASND?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASND. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ascendis Pharma A/S's investment landscape.